Brief: Arrowhead Pharmaceuticals Announces ARO-MAPT Interim Phase 1/2a Clinical Data Demonstrating Deep and Durable Tau Reductions in Healthy Volunteers
14/10/2026 13:21
BRIEF-Arrowhead Pharmaceuticals Announces ARO-MAPT Interim Phase 1/2a Clinical Data Demonstrating Deep and Durable Tau Reductions in Healthy Volunteers Oct 14 (Reuters) - Arrowhead Pharmaceuticals, Inc. ARWR.O:
ARROWHEAD PHARMACEUTICALS ANNOUNCES ARO-MAPT INTERIM PHASE 1/2A CLINICAL DATA DEMONSTRATING DEEP AND DURABLE TAU REDUCTIONS IN HEALTHY VOLUNTEERS
ARROWHEAD PHARMACEUTICALS - TO COMPLETE DOSING IN HEALTHY VOLUNTEERS, DATA UPDATES EXPECTED IN 2027
ARROWHEAD PHARMACEUTICALS - ARO-MAPT GENERALLY WELL TOLERATED, MOST ADVERSE EVENTS MILD, NO SERIOUS TEAES REPORTED
Source text: ID:nBw9clLSKa
Further company coverage: ARWR.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Arrowhead Pharmaceuticals
See all newsBrief: Uk's MHRA Authorises Redemplo For Adults With Familial Chylomicronaemia Syndrome
US STOCKS ON THE MOVE-Netflix, Coinbase Global, Accenture
US STOCKS ON THE MOVE-Bending Spoons, Skydance, Albertsons
US STOCKS ON THE MOVE-Albertsons, GlobalFoundries, American Electric Power, Fastenal
Brief: Arrowhead Pharmaceuticals Announces ARO-MAPT Interim Phase 1/2a Clinical Data Demonstrating Deep and Durable Tau Reductions in Healthy Volunteers